Atherosclerosis, a dominant and growing cause of death and disability worldwide, involves
inflammation from its inception to the emergence of complications. Targeting inflammatory …

Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …

Most older individuals develop inflammageing, a condition characterized by elevated levels
of blood inflammatory markers that carries high susceptibility to chronic morbidity, disability …

Background Inflammation is causally related to atherothrombosis. Treatment with
canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin …

Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

The concept that inflammation participates pivotally in the pathogenesis of atherosclerosis
and its complications has gained considerable attention, but has not yet entered clinical …

Myocardial infarction (MI), as a result of thrombosis or vascular occlusion, is the most
prevalent cause of morbidity and mortality among all cardiovascular diseases. The …

Observations on human and experimental atherosclerosis, biomarker studies, and now a
large-scale clinical trial support the operation of immune and inflammatory pathways in this …

Inflammation is an important driver of atherosclerosis, the underlying pathology of
cardiovascular diseases. Therefore, therapeutic targeting of inflammatory pathways is …

The statins have been used for 30 years to prevent coronary artery disease and stroke. Their
primary mechanism of action is the lowering of serum cholesterol through inhibiting hepatic …